GGrantIndex
Sort

48,018 grants matching immunotherapy

Bladder Cancer Program

$1,057,180
Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Developing novel LOX inhibitors to target chemotherapy resistant TNBC

$1,057,068
Ozgur Sahin · Loxigen, Inc. · R42 · FY2025 · CA

PATHWAYS TO TOLERANCE IN HUMAN ISLET TRANSPLANTATION

$1,055,963
University Of Miami School Of Medicine · R01 · FY2003 · DK

Determinants of response to cancer immunotherapy

$1,055,838
Lawrence Fong · Fred Hutchinson Cancer Center · R35 · FY2025 · CA

ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER

$1,055,613
Johns Hopkins University · U19 · FY2003 · CA

Integrating systems immunology with immunometabolism and cancer immunity

$1,055,460
Hongbo Chi · St. Jude Children'S Research Hospital · R35 · FY2023 · CA

Integrating systems immunology with immunometabolism and cancer immunity

$1,055,460
Hongbo Chi · St. Jude Children'S Research Hospital · R35 · FY2022 · CA

Investigation of role of microbiota in development, progression and therapy of cancers

$1,055,069
Amiran Dzutsev · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERS

$1,054,912
Peter Jahrling · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides

$1,054,354
Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Collaborative Protein Technology Resource - Nano-Scale Protein Analysis Section

$1,053,823
Noemi Kedei · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA

Targeting eIF4A1 in drug-resistant breast cancer stem-like cells

$1,053,488
Dayanidhi Raman · University Of Toledo Health Sci Campus · R01 · FY2025 · CA

FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION

$1,052,768
Clinton Grubbs · University Of Alabama At Birmingham · N01 · FY2019 · CA

Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV Infection

$1,052,100
Alejandro Benjamin Balazs · Massachusetts General Hospital · DP1 · FY2024 · DA

Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV Infection

$1,052,100
Alejandro Benjamin Balazs · Massachusetts General Hospital · DP1 · FY2025 · DA

Finding Sleeping Beauty: T Cell Biosensors for Dormant Cancer Detection

$1,052,030
Gabriel A Kwong · Georgia Institute Of Technology · DP1 · FY2024 · CA

Adenosine Receptor Agonists as an Immunotherapy for Biodefense

$1,051,580
Peter B Ernst · University Of Virginia · U01 · FY2007 · AI

A STINGing vaccine for TB

$1,051,436
William Ramses Bishai · Johns Hopkins University · R01 · FY2022 · AI

Liver Cancer Program

$1,051,369
Anuradha Budhu · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN AIDS

$1,051,286
Beth Israel Medical Ctr (New York) · U01 · FY2001 · AI

Targeted immune therapies in heart transplantation

$1,050,893
Reza Abdi · Brigham And Women'S Hospital · R35 · FY2023 · HL

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications

$1,050,724
Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2010 · CA

Basic Research Support for the CCR

$1,050,724
Robert Wiltrout · Division Of Basic Sciences - Nci · ZIC · FY2009 · CA

Coordinating and Data Management Center for Acquired Resistance to Therapy Network

$1,050,404
Alan David Hutson · Roswell Park Cancer Institute Corp · U24 · FY2022 · CA

Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.

$1,050,313
Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · U01 · FY2022 · CA